11-Dec-2025
Wave Life Sciences Announces Public Offering for $402.5 Million
TipRanks (Thu, 11-Dec 6:30 AM ET)
Wave Life Sciences’ $350 Million Upsized Offering Highlights Expanding Investor Demand
Market Chameleon (Wed, 10-Dec 2:08 AM ET)
Wave Life Sciences prices upsized $350M stock offering
Seeking Alpha News (Wed, 10-Dec 1:53 AM ET)
Wave Life Science prices upsized $350M stock ofeering
Seeking Alpha News (Wed, 10-Dec 1:53 AM ET)
Globe Newswire (Tue, 9-Dec 9:50 PM ET)
What's Going On With Wave Life Sciences Stock Tuesday?
Benzinga (Tue, 9-Dec 2:11 PM ET)
Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007
Seeking Alpha News (Tue, 9-Dec 11:49 AM ET)
Why is Biotech Stock iBio Up over 50%?
TipRanks (Tue, 9-Dec 8:57 AM ET)
Analysts’ Top Healthcare Picks: Phreesia (PHR), Wave Life Sciences (WVE)
TipRanks (Tue, 9-Dec 8:30 AM ET)
Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
TipRanks (Tue, 9-Dec 7:25 AM ET)
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Wave Life Sciences Ltd. - trades on the NASDAQ stock market under the symbol WVE.
As of December 11, 2025, WVE stock price declined to $16.75 with 14,735,922 million shares trading.
WVE has a beta of 1.86, meaning it tends to be more sensitive to market movements. WVE has a correlation of 0.18 to the broad based SPY ETF.
WVE has a market cap of $2.80 billion. This is considered a Mid Cap stock.
Last quarter Wave Life Sciences Ltd. - reported $8 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.
In the last 3 years, WVE traded as high as $21.73 and as low as $3.15.
The top ETF exchange traded funds that WVE belongs to (by Net Assets): IWM, IBB, IWO, VXF, SCHA.
WVE has underperformed the market in the last year with a return of +11.9%, while SPY returned +15.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in WVE shares. However, WVE has outperformed the market in the last 3 month and 2 week periods, returning +126.7% and +118.4%, while SPY returned +5.9% and +1.4%, respectively. This indicates WVE has been having a stronger performance recently.
WVE support price is $19.13 and resistance is $21.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WVE shares will trade within this expected range on the day.